39 related articles for article (PubMed ID: 24160301)
1. The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease.
Lowenthal J; Hull SC; Pearson SD
N Engl J Med; 2012 Aug; 367(6):488-90. PubMed ID: 22873528
[No Abstract] [Full Text] [Related]
2. COVID-19 and off label use of drugs: an ethical viewpoint.
Shojaei A; Salari P
Daru; 2020 Dec; 28(2):789-793. PubMed ID: 32385829
[TBL] [Abstract][Full Text] [Related]
3. When are medical apps medical? Off-label use and the Food and Drug Administration.
Krieger WH
Digit Health; 2016; 2():2055207616662782. PubMed ID: 29942563
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Early Mental Health Diagnosis and Medication Treatment in a Medicaid-Insured Birth Cohort.
Pennap D; Zito JM; Santosh PJ; Tom SE; Onukwugha E; Magder LS
JAMA Pediatr; 2018 Jun; 172(6):576-584. PubMed ID: 29710205
[TBL] [Abstract][Full Text] [Related]
5. Use of contrast media in diagnostic imaging: medico-legal considerations.
Pomara C; Pascale N; Maglietta F; Neri M; Riezzo I; Turillazzi E
Radiol Med; 2015 Sep; 120(9):802-9. PubMed ID: 26082145
[TBL] [Abstract][Full Text] [Related]
6. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.
Ignatowski TA; Spengler RN; Dhandapani KM; Folkersma H; Butterworth RF; Tobinick E
CNS Drugs; 2014 Aug; 28(8):679-97. PubMed ID: 24861337
[TBL] [Abstract][Full Text] [Related]
7. Immediate neurological recovery following perispinal etanercept years after brain injury.
Tobinick E; Rodriguez-Romanacce H; Levine A; Ignatowski TA; Spengler RN
Clin Drug Investig; 2014 May; 34(5):361-6. PubMed ID: 24647830
[TBL] [Abstract][Full Text] [Related]
8. Off-label prescriptions for atopic dermatitis in Europe.
Bieber T; Straeter B
Allergy; 2015 Jan; 70(1):6-11. PubMed ID: 25074686
[TBL] [Abstract][Full Text] [Related]
9. [Off-label prescribing].
Blondon K; Desmeules J; Vogt-Ferrier N; Besson M; Kondo-Oestreicher M; Dayer P
Rev Med Suisse; 2008 Jul; 4(165):1661-5. PubMed ID: 18767292
[TBL] [Abstract][Full Text] [Related]
10. Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use.
Vox F; Capron AM; Kraus MF; Alexander GC; Kirschner KL
PM R; 2013 Oct; 5(10):882-9. PubMed ID: 24160301
[No Abstract] [Full Text] [Related]
11. Informed consent in off-label use and incapacitated persons.
Elger CE; Hoppe C
Epilepsia; 2009 Dec; 50 Suppl 12():79-80. PubMed ID: 19941536
[No Abstract] [Full Text] [Related]
12. Staying on track when prescribing off-label.
Fitzgerald AS; O'Malley PG
Am Fam Physician; 2014 Jan; 89(1):4-5. PubMed ID: 24444499
[No Abstract] [Full Text] [Related]
13. Off-label prescribing of medications for pain: maintaining optimal care at an intersection of law, public policy, and ethics.
Ruble J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):146-52. PubMed ID: 22764854
[TBL] [Abstract][Full Text] [Related]
14. Going off-label without venturing off-course: evidence and ethical off-label prescribing.
Largent EA; Miller FG; Pearson SD
Arch Intern Med; 2009 Oct; 169(19):1745-7. PubMed ID: 19858430
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
